loading page

CLINICAL MANAGEMENT OF LUNG CANCER PATIENTS WITH RESPIRATORY SYMPTOMS DURING EPIDEMIC OF COVID-19
  • +1
  • Pınar Kabalak,
  • Derya Kızılgöz,
  • Suna Kavurgacı,
  • Ülkü Yılmaz
Pınar Kabalak
Atatürk Göğüs Hastalıkları Ve Göğüs Cerrahisi Eğitim Ve Araştırma Hastanesi

Corresponding Author:[email protected]

Author Profile
Derya Kızılgöz
Atatürk Göğüs Hastalıkları Ve Göğüs Cerrahisi Eğitim Ve Araştırma Hastanesi
Author Profile
Suna Kavurgacı
Atatürk Göğüs Hastalıkları Ve Göğüs Cerrahisi Eğitim Ve Araştırma Hastanesi
Author Profile
Ülkü Yılmaz
Atatürk Göğüs Hastalıkları Ve Göğüs Cerrahisi Eğitim Ve Araştırma Hastanesi
Author Profile

Abstract

Objective: There are many clinical conditions that need to be followed and treated during pandemic like lung cancer. Carrying out health care for these patients who are immune-suppresive require extra care. Method: Among 108 lung cancer patients who has been hospitalized during pandemic, 18 of them with respiratory symptoms were evaluated. Results: Median age was 64±9.4 with male predominance (male n=16, female n=2). Thirteen of them was non-small cell lung cancer (NSCLC) and 5 of them was small cell lung cancer (SCLC). Nine (50%) patients were receiving chemotherapy. The most common symptom was shortness of breath (n=14, 77.8%), followed by fever (n=10, 55.6%). Findings confirmed on computed thorax tomography (CTT) were as follows: Consolidation (n=8, 44.4%), ground glass opacities (n=8, 44.4%) and thoracic tumour/mediastinal-hilar lymphadenopathy (n=3, 16.7%). Hypoxia was seen in 11 patients (61.1.%). Twelve patients had elevation of LDH (median=302±197) and lymphopenia (median=1055±648). There were 5 (27.7%) highly suspected cases for COVID-19. Any of their nasopharyngeal swap was positive. Two of these 5 patients received COVID-19 specific treatment even they have negative PCR results for 3 times. They responded well both clinical and radiological. For one case with SCLC receiving immunotherapy metil-prednisolone was initiated for radiation pneumonitis after excluding COVID-19. Conclusion: In line with the health policies of the countries and the adequacy of the health system, the necessity of a multidisciplinary approach in the management and treatment of complications in patients with lung cancer becomes even more important in this pandemic.
04 Jul 2020Submitted to International Journal of Clinical Practice
16 Jul 2020Submission Checks Completed
16 Jul 2020Assigned to Editor
22 Sep 2020Reviewer(s) Assigned
03 Jan 2021Review(s) Completed, Editorial Evaluation Pending
28 Feb 20211st Revision Received
02 Mar 2021Submission Checks Completed
02 Mar 2021Assigned to Editor
03 Mar 2021Reviewer(s) Assigned
25 Mar 2021Review(s) Completed, Editorial Evaluation Pending
18 Apr 20212nd Revision Received
19 Apr 2021Submission Checks Completed
19 Apr 2021Assigned to Editor
01 Jun 2021Reviewer(s) Assigned
15 Oct 2021Review(s) Completed, Editorial Evaluation Pending
27 Oct 2021Editorial Decision: Accept